Upregulation of inflammatory pathways and resistance markers such as ABCB1 were associated with poorer MRD response to BCL2 inhibition, suggesting possible biological vulnerabilities that could be leveraged to improve treatment efficacy and outcomes of patients with CLL. This evidence concerns the gene BCL2 and B-cell chronic lymphocytic leukemia.